FDMT - Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released | Benzinga
4D Molecular Therapeutics (NASDAQ:FDMT) released data from a clinical trial for cystic fibrosis lung disease.
What Happened: The company unveiled results from the 4D-710 Phase 1/2 AEROW study:
- At high dose – 2E15 vg (n=4), complete resolution of previously reported serious adverse event (SAE) was observed; ppFEV1 in this participant improved by 6% from baseline to month 12.
- Lung biopsy results: No evidence of inflammation or toxicity from histological analysis of tissue samples
- Widespread expression of CFTR protein compared to normal (non-CF) lung samples and no increase vs. 1E15 vg dose
- There is evidence of consistent CFTR protein expression ...